全文获取类型
收费全文 | 1107377篇 |
免费 | 76650篇 |
国内免费 | 3998篇 |
专业分类
耳鼻咽喉 | 15242篇 |
儿科学 | 35051篇 |
妇产科学 | 28876篇 |
基础医学 | 156974篇 |
口腔科学 | 30106篇 |
临床医学 | 99742篇 |
内科学 | 207960篇 |
皮肤病学 | 24709篇 |
神经病学 | 82909篇 |
特种医学 | 43916篇 |
外国民族医学 | 218篇 |
外科学 | 165834篇 |
综合类 | 29456篇 |
现状与发展 | 14篇 |
一般理论 | 263篇 |
预防医学 | 77269篇 |
眼科学 | 25402篇 |
药学 | 90175篇 |
46篇 | |
中国医学 | 5469篇 |
肿瘤学 | 68394篇 |
出版年
2021年 | 9356篇 |
2019年 | 8830篇 |
2018年 | 12405篇 |
2017年 | 10060篇 |
2016年 | 11081篇 |
2015年 | 12887篇 |
2014年 | 17361篇 |
2013年 | 24148篇 |
2012年 | 33535篇 |
2011年 | 35442篇 |
2010年 | 21165篇 |
2009年 | 19672篇 |
2008年 | 32109篇 |
2007年 | 34245篇 |
2006年 | 34677篇 |
2005年 | 32733篇 |
2004年 | 30925篇 |
2003年 | 29657篇 |
2002年 | 28422篇 |
2001年 | 60779篇 |
2000年 | 62128篇 |
1999年 | 51540篇 |
1998年 | 12790篇 |
1997年 | 11355篇 |
1996年 | 11289篇 |
1995年 | 10553篇 |
1994年 | 9568篇 |
1993年 | 8989篇 |
1992年 | 37913篇 |
1991年 | 36417篇 |
1990年 | 35851篇 |
1989年 | 34377篇 |
1988年 | 30930篇 |
1987年 | 30043篇 |
1986年 | 28256篇 |
1985年 | 26472篇 |
1984年 | 19196篇 |
1983年 | 16124篇 |
1982年 | 8829篇 |
1979年 | 17032篇 |
1978年 | 11404篇 |
1977年 | 10229篇 |
1976年 | 8837篇 |
1975年 | 10068篇 |
1974年 | 11651篇 |
1973年 | 11273篇 |
1972年 | 10754篇 |
1971年 | 10092篇 |
1970年 | 9252篇 |
1969年 | 8938篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Hassen Lena M. Albarrak Rana A. Albahlal Reem A. Alsaqabi Dimah K. Hassen Ikhlass M. Daghestani Maha H. Alqurtas Eman M. Alkhalaf Abdulaziz T. Bedaiwi Mohammed K. Omair Mohammed A. Almaghlouth Ibrahim A. 《Quality of life research》2022,31(11):3229-3239
Quality of Life Research - The COVID-19 pandemic might add to the stressors experienced by people living with rheumatic diseases. This study aimed to examine rheumatic patients’ functional... 相似文献
3.
Molnár B. Aroca S. Dobos A. Orbán K. Szabó J. Windisch P. Stähli A. Sculean A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with... 相似文献
4.
5.
6.
7.
8.
Jesus K Yamamoto-Furusho Norma N Parra-Holgu n 《World journal of gastroenterology : WJG》2021,27(48):8242-8261
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years. 相似文献
9.
10.
Qiangsheng He Chongfei Huang Xiwen Qin Yuanyuan Yu Di Tang Junjie Huang Zi Chong Kuo Yuyao Ling Deli Mao Bin Xia Wenjing Li Kuiqing Lu Man Yang Yulong He Wenbo Meng Jinqiu Yuan Yihang Pan 《International journal of cancer. Journal international du cancer》2023,153(5):942-949
Recent epidemiological studies suggested that proton pump inhibitor (PPI) use was associated with an increased risk of biliary tract cancer (BTC), however, confounders were not adequately controlled. Our study aimed to evaluate PPI use and subsequent risk of BTC and its subtypes in three well-established cohorts. We conducted a pooled analysis of the subjects free of cancers in UK Biobank (n = 463 643), Nurses' Health Study (NHS, n = 80 235) and NHS II (n = 95 869). Propensity score weighted Cox models were used to estimate marginal HRs of PPIs use on BTC risk, accounting for potential confounders. We documented 284 BTC cases in UK Biobank (median follow-up: 7.6 years), and 91 cases in NHS and NHS II cohorts (median follow-up: 15.8 years). In UK biobank, PPI users had a 96% higher risk of BTC compared to nonusers in crude model (HR 1.96, 95% CI 1.44-2.66), but the effect was attenuated to null after adjusting for potential confounders (HR 0.95, 95% CI 0.60-1.49). PPI use was not associated with risk of BTC in the pooled analysis of three cohorts (HR 0.93, 95% CI 0.60-1.43). We also observed no associations between PPI use with risk of intrahepatic (HR 1.00, 95% CI 0.49-2.04), extrahepatic bile duct (HR 1.09, 95% CI 0.52-2.27) and gallbladder cancers (HR 0.66, 95% CI 0.26-1.66) in UK Biobank. In summary, regular use of PPIs was not associated with the risk of BTC and its subtypes. 相似文献